Literature DB >> 10147023

Cost-utility analysis of early thrombolytic therapy.

D Castiel1, C Hervé, M Gaillard, J L Bollaert, M Soula.   

Abstract

167 patients suffering from acute myocardial infarction (AMI) were recruited from 12 cardiology centres and given thrombolytic treatment. Cost-utility analyses were performed and a cost-utility ratio was computed according to time of initiation of thrombolysis after the AMI and the location of the infarct. Early thrombolysis ( less than 3 hours) proved to cost about the same per QALY ($US3734 vs $US3577) as late thrombolysis ( greater than 3 hours), although posterior infarcts cost slightly more per QALY ($3433 vs $2996) than anterior infarcts. Quality of life coefficients for all patients after the AMI were judged to be about 40% less than before the AMI. Thus, in terms of resources consumed and patient well-being, time of treatment initiation or location of the infarct were less significant than the fact of having an AMI. In terms of quality of life, the best strategy is that which seeks to prevent AMI occurring.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 10147023     DOI: 10.2165/00019053-199201060-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

Review 1.  Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol.

Authors:  W B Stason
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

2.  Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective.

Authors:  A E Fletcher; C J Bulpitt
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

3.  Trends in the incidence of myocardial infarction and in associated mortality and morbidity in a large employed population, 1957-1983.

Authors:  S Pell; W E Fayerweather
Journal:  N Engl J Med       Date:  1985-04-18       Impact factor: 91.245

4.  Principles of cost-effectiveness research.

Authors:  T G Ganiats; L J Schneiderman
Journal:  J Fam Pract       Date:  1988-07       Impact factor: 0.493

5.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

6.  Cost-benefit analysis of thrombolytic therapy.

Authors:  C Herve; D Castiel; M Gaillard; R Boisvert; V Leroux
Journal:  Eur Heart J       Date:  1990-11       Impact factor: 29.983

7.  Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands.

Authors:  F Vermeer; M L Simoons; C de Zwaan; G A van Es; F W Verheugt; A van der Laarse; D C van Hoogenhuyze; A J Azar; F J van Dalen; J Lubsen
Journal:  Br Heart J       Date:  1988-05

8.  Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

9.  Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.

Authors: 
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

10.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

View more
  7 in total

1.  Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

Authors:  Kit N Simpson; Michelle P Luo; Elinor C Chumney; Martin S King; Scott Brun
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 2.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

Review 3.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

4.  Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data.

Authors:  Kit N Simpson; Birgitta Dietz; Robert W Baran; Kevin W Garren; Sharon A Riddler; Menaka Bhor; Richard H Haubrich
Journal:  Cost Eff Resour Alloc       Date:  2011-05-08

5.  Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.

Authors:  Kit N Simpson; Walter J Jones; Rukmini Rajagopalan; Birgitta Dietz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

Authors:  Kit N Simpson; Walter J Jones; Rukmini Rajagopalan; Birgitta Dietz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

Authors:  Emanuela Foglia; Paolo Bonfanti; Giuliano Rizzardini; Erminio Bonizzoni; Umberto Restelli; Elena Ricci; Emanuele Porazzi; Francesca Scolari; Davide Croce
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.